Stereotaxis enters ATM equity agreement to sell up to $50M of common stock

Stereotaxis, Inc.

Agreement with Roth Capital Partners for at-the-market offering of up to $50M in common stock.
Proceeds to fund working capital, R&D, and accelerated commercialization of innovation pipeline.
Placement fee of up to 3.0% of gross sales; expense reimbursement up to $50k initial and $5k per quarter.
Shares sold under existing Form S-3 shelf registration (File No. 333-272102); company not obligated to sell.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.